Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes -: The Berlin Diabetes Mellitus (BeDiaM) Study
Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes -: The Berlin Diabetes Mellitus (BeDiaM) Study
复制标题
DOI：
10.2337/diabetes.51.8.2653
复制
发表时间：
2002-08-01
期刊：
影响因子：
7.7
通讯作者：
Brand, E
中科院分区：
文献类型：
--
作者：
Herrmann, SM;Ringel, J;Brand, E
编码过氧化物酶体增殖物激活受体（PPAR）-γ 2的基因的Pro 12 Ala多态性最近被证明与2型糖尿病相关。在本分析中，我们研究了PPAR-gamma 2 Pro 12 Ala是否与2型糖尿病的微血管并发症，如蛋白尿、终末期肾功能衰竭（ESRF）或视网膜病变相关。总共有445名2型糖尿病患者参加了柏林糖尿病研究，我们对他们进行了蛋白尿、ESRF和视网膜病变的检测，对他们进行了PPAR-gamma 2 Pro 12 Ala多态性的基因分型。我们还测量了潜在的重要协变量，如血压、BMI、糖尿病病程、糖化血红蛋白、血清肌酐和血脂。在445例2型糖尿病患者中（平均年龄59.3岁），Pro 12 Ala基因型分布符合Hardy-Weinberg平衡（P = 0.42）。Ala 12等位基因频率为0.14。校正协变量后，118例Ala 12等位基因携带者的尿白蛋白排泄量（UAE）显著低于327例非携带者（17.1 vs 25.8 mg/d; P = 0.01）。在PPAR-gamma Ala 12等位基因携带者中观察到的UAE相对于非携带者（P = 0.003）的降低百分比从0.2%（P = 0.99）上升到54%（P = 0.008），当糖尿病持续时间从12个月增加到12个月时，UAE降低百分比上升到70%（P = 0.01）。
The Pro12Ala polymorphism of the gene encoding the peroxisome proliferator-activated receptor (PPAR)-gamma2 has recently been shown to be associated with type 2 diabetes. In the present analysis, we investigated whether PPAR-gamma2 Pro12Ala was associated with microvascular complications of type 2 diabetes, such as albuminuria, end-stage renal failure (ESRF), or retinopathy. total of 445 patients with type 2 diabetes who were enrolled in the Berlin Diabetes Mellitus Study and in whom we determined albuminuria and the presence of ESRF and retinopathy were genotyped for the PPAR-gamma2 Pro12Ala polymorphism. We also measured potentially important covariables, such as blood pressure, BMI, duration of diabetes, glycosylated hemoglobin, serum creatinine, and serum lipids. Among 445 patients with type 2 diabetes (mean age 59.3 years), the Pro12Ala genotype distribution was in Hardy-Weinberg equilibrium (P = 0.42). The Ala12 allele frequency was 0.14. With adjustment for covariables, the 118 Ala12 allele carriers had significantly lower urinary albumin excretion (UAE) than the 327 noncarriers (17.1 vs. 25.8 mg/d; P = 0.01). The percentage decrease in UAE observed in PPAR-gamma Ala12 allele carriers relative to noncarriers (P = 0.003) rose from 0.2% (P = 0.99) to 54% (P = 0.008) and to 70% (P = 0.01) when the duration of diabetes increased from